EUROAPI: insider trades · France · AMF

About EUROAPI

EUROAPI is a leading European player in active pharmaceutical ingredients (APIs) and intermediates used in the manufacture of medicines for both human and veterinary use. The company develops, manufactures, markets and distributes APIs through two complementary commercial engines: API Solutions, which covers a broad portfolio of standard and specialty molecules, and CDMO activities (Contract Development and Manufacturing Organization), through which EUROAPI supports pharmaceutical and biotech customers in the development and production of more complex molecules. The group states that it manages a portfolio of roughly 200 APIs and that its industrial footprint is entirely located in Europe. EUROAPI’s recent history is closely tied to Sanofi. The company was created from a carve-out of API and intermediate activities previously embedded within Sanofi, and it was listed on Euronext Paris on May 6, 2022, under ticker EAPI and ISIN FR0014008VX5. At the time of the listing, Sanofi remained a long-term strategic partner while EUROAPI gained greater operational and commercial independence. From a competitive standpoint, EUROAPI relies on three key strengths: a broad product base, diverse manufacturing technologies, and the ability to serve highly complex molecules. The company highlights expertise in fermentation, complex chemical synthesis, peptides, oligonucleotides, prostaglandins, corticosteroids, hormones, anti-infectives, opiates and other high-value molecules. In its latest public communications, EUROAPI says it is the global number one in small molecules APIs by sales and reported 2024 sales of €911.9 million. Operationally, EUROAPI relies on a European manufacturing network that includes five to six production sites, depending on how the footprint is described in different company and market materials, with facilities in France, the United Kingdom, Germany, Italy and Hungary. This footprint enables the group to serve customers in more than 80 countries and to address a global client base of pharmaceutical companies, biotech firms and generic-drug manufacturers. The group also maintains an international R&D organization designed to accelerate innovation, develop new processes and strengthen its CDMO offering. EUROAPI’s notable features include its exposure to technically demanding API markets, its deeply European industrial base, and a strategy increasingly focused on the most profitable products and contracts. The company’s 2024 Universal Registration Document emphasizes portfolio rationalization and profitability improvement, while the 2026 outlook still points to a challenging commercial environment.